Table 3 Effect on progression of structural joint damage based on first and fourth quartiles of baseline disease characteristics
Baseline characteristicFirst quartile (lowest)Fourth quartile (highest)
Placebo plus MTXRituximab plus MTXPlacebo plus MTXRituximab plus MTX
Disease duration (quartile range)1 to 616 to 48
    No. of patients46694470
    Change in TSG3.231.011.340.65
Baseline TSG (quartile range)1 to 1966 to 181
    No. of patients44714470
    Change in TSG1.50.892.731.10
DAS28 (quartile range)3 to 68 to 9
    No. of patients47684569
    Change in TSG2.020.414.172.4
CRP (quartile range)0 to 15 to 24
    No. of patients51714866
    Change in TSG0.910.464.862.23
HAQ-DI (quartile range)0 to 22 to 3
    No. of patients47734753
    Change in TSG1.351.081.661.02
  • CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; TSG, total Genant-modified Sharp score.